It is also essential to highlight that while higher levels of MET amplification tend to correlate with a better response to c-MET inhibitors, overall responses in MET amplified tumor are low, suggesting that wt c-MET may be a poor oncogenic driver even when overexpressed. This evidence concerns the gene MET and neoplasm.